u/yellowbai

GLP-1 drugs like Ozempic/Wegovy are showing strong real-world adoption and increasing trust among GPs. Once insurers see these drugs reduce long-term healthcare costs, prescription volumes could scale massively — even if generics eventually appear. The market is mispricing Novo Nordisk’s long-term growth runway in weight-loss and metabolic disease. Slow insurance adoption, policy/pricing pressure, competition from Lilly and others, or clinical/safety setbacks could invalidate the thesis. No other actionable trade ideas in this post.